SCHEMBL1765140

SCHEMBL1765140

CC1(C)CC(N)CC(C)(C)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 1/20 0.31
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
LMNA P02545 1/20 0.31
ESR1 P03372 1/20 0.31
ADRB3 P13945 1/20 0.31
ACHE P22303 1/20 0.31
OPRK1 P41145 1/20 0.31
MTOR P42345 1/20 0.31
HTT P42858 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2A Q12879 1/20 0.31
GRIN2B Q13224 1/20 0.31
GRIN2C Q14957 1/20 0.31
GRIN3A Q8TCU5 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
NFKB1 P19838 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1793669 0.97 LMNA (0.33) LMNAGRIN1GRIN2A
SCHEMBL1584140 0.86
SCHEMBL1003423 0.83 LMNA (0.31) SLC22A1GRIN2DGRIN3BLMNAESR1
Hydrochloric Acid SCHEMBL14941077 0.83
SCHEMBL17187444 0.81
SCHEMBL19656256 0.79 ALDH1A1 (0.33) ESR1
SCHEMBL23981409 0.77 GRIN2D (0.34) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL8739143 0.77 ALDH1A1 (0.33)
SCHEMBL47332 0.77 ALDH1A1 (0.33)
SCHEMBL20604028 0.77 ALDH1A1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2867227-B1 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2018-11-21 EP claimed
US-9487483-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2016-11-08 US claimed
US-20150148349-A1 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2015-05-28 US claimed
EP-2867227-A2 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF Novartis AG (CH) 2015-05-06 EP claimed
WO-2014002058-A2 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2014-01-03 WO claimed
US-20230159496-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2023-05-25 US disclosed
WO-2023008572-A1 ONIUM SALT, BLOCKING AGENT DISSOCIATION CATALYST FOR BLOCKED ISOCYANATE, BLOCKED ISOCYANTE COMPOSITION INCLUDING BLOCKING AGENT DISSOCIATION CATALYST, THERMOSETTING RESIN COMPOSITION, AND CURED PRODUCT AND MANUFACTURING METHOD THEREFOR 広栄化学株式会社 2023-02-02 WO disclosed
WO-2022260057-A1 CURABLE COMPOSITION モメンティブ・パフォーマンス・マテリアルズ・ジャパン合同会社 2022-12-15 WO disclosed
US-11365175-B2 Aromatic amides having a fungicidal activity, their agronomic compositions and relative preparation method ISAGRO S.P.A. (IT) 2022-06-21 US disclosed
EP-3412727-B1 AQUEOUS DISPERSION, METHOD FOR MANUFACTURING THE SAME, AND IMAGE FORMING METHOD FUJIFILM CORP (JP) 2021-12-08 EP disclosed
WO-2021221084-A1 BLOCKED ISOCYANATE COMPOSITION, HEAT-CURABLE RESIN COMPOSITION, CURED PRODUCT, PRODUCTION METHOD THEREFOR, AMIDATE COMPOUND, AND CATALYST FOR DISSOCIATION OF BLOCKING AGENT FOR BLOCKED ISOCYANATES 広栄化学株式会社 2021-11-04 WO disclosed
EP-3131994-B1 FAST CURING MIGRATION-FREE COMPOSITION BASED ON ORGANIC POLYMERS CONTAINING SILANE GROUPS SIKA TECH AG (CH) 2021-06-09 EP disclosed
EP-1196388-A2 FUNGICIDAL HETEROCYCLIC AROMATIC AMIDES AND THEIR COMPOSITIONS, METHODS OF USE AND PREPARATION Dow AgroSciences LLC (US) 2002-04-17 EP disclosed
US-6355660-B1 HETEROCYCLIC FUNGICIDES SUBSTITUTED WITH AMIDE GROUPS DOW AGROSCIENCES LLC 2002-03-12 US disclosed
WO-2001014339-A2 FUNGICIDAL HETEROCYCLIC AROMATIC AMIDES AND THEIR COMPOSITIONS, METHODS OF USE AND PREPARATION DOW AGROSCIENCES LLC (US) 2001-03-01 WO disclosed
WO-2001005769-A2 FUNGICIDAL HETEROCYCLIC AROMATIC AMIDES AND THEIR COMPOSITIONS, METHODS OF USE AND PREPARATION DOW AGROSCIENCES LLC (US) 2001-01-25 WO disclosed
EP-0355443-A2 Cyclic process for the preparation of (cyclo)aliphatic diisocyanates HÜLS AKTIENGESELLSCHAFT (DE) 1990-02-28 EP disclosed
US-4504681-A Catalytic oxidation of primary amines to oximes by elemental oxygen ALLIED CORPORATION (US) 1985-03-12 US disclosed
US-4337358-A Process for oxidizing primary amines to oximes by elemental oxygen ALLIED CORPORATION (US) 1982-06-29 US disclosed
EP-0043445-A1 Process for oxidizing primary amines to oximes by elemental oxygen ALLIED CORPORATION (US) 1982-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159496-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 SLC22A1 4824/4885GRIN2D 2492/4885GRIN3B 1174/4885
US-20150148349-A1 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF C5, C3AR1, C9 SLC22A1 3943/4885GRIN2D 3969/4885GRIN3B 1860/4885
US-11365175-B2 Aromatic amides having a fungicidal activity, their agronomic compositions and relative preparation method CYP51A1, NAT1, AADAC SLC22A1 2737/4885GRIN2D 2321/4885GRIN3B 4417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.